These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 35665971)

  • 1. Efficacy and toxicity of surufatinib in neuroendocrine tumors: A systematic review and meta-analysis.
    Ali MA; Shah SS; Tahir N; Rehman S; Saeed M; Bajwa SF; Ali R; Aiman W; Anwar MY
    J Neuroendocrinol; 2022 Jul; 34(7):e13149. PubMed ID: 35665971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep).
    Li J; Cheng Y; Bai C; Xu J; Shen L; Li J; Zhou Z; Li Z; Chi Y; Yu X; Li E; Xu N; Liu T; Lou W; Bai Y; Yuan X; Wang X; Yuan Y; Chen J; Guan S; Fan S; Su W
    Eur J Cancer; 2022 Jul; 169():1-9. PubMed ID: 35489301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment-related adverse events as predictive biomarkers of efficacy in patients with advanced neuroendocrine tumors treated with surufatinib: results from two phase III studies.
    Li J; Cheng Y; Bai C; Xu J; Shen L; Li J; Zhou Z; Li Z; Chi Y; Yu X; Li E; Xu N; Liu T; Lou W; Bai Y; Yuan X; Wang X; Yuan Y; Chen J; Guan S; Fan S; Su W
    ESMO Open; 2022 Apr; 7(2):100453. PubMed ID: 35344750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study.
    Xu J; Shen L; Bai C; Wang W; Li J; Yu X; Li Z; Li E; Yuan X; Chi Y; Yin Y; Lou W; Xu N; Bai Y; Zhang T; Xiu D; Wang X; Yuan Y; Chen J; Qin S; Jia R; Lu M; Cheng Y; Zhou Z; Li J; He J; Su W
    Lancet Oncol; 2020 Nov; 21(11):1489-1499. PubMed ID: 32966810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surufatinib combined with transarterial embolization versus surufatinib monotherapy in patients with liver metastatic neuroendocrine tumors: Study protocol for a prospective, randomized, controlled trial.
    Li R; Li X; You X; Su M; Liu Y; Ke N; Cao D
    Cancer Med; 2024 Apr; 13(8):e7131. PubMed ID: 38629255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study.
    Xu J; Shen L; Zhou Z; Li J; Bai C; Chi Y; Li Z; Xu N; Li E; Liu T; Bai Y; Yuan Y; Li X; Wang X; Chen J; Ying J; Yu X; Qin S; Yuan X; Zhang T; Deng Y; Xiu D; Cheng Y; Tao M; Jia R; Wang W; Li J; Fan S; Peng M; Su W
    Lancet Oncol; 2020 Nov; 21(11):1500-1512. PubMed ID: 32966811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II Trial.
    Xu J; Li J; Bai C; Xu N; Zhou Z; Li Z; Zhou C; Jia R; Lu M; Cheng Y; Mao C; Wang W; Cheng K; Su C; Hua Y; Qi C; Li J; Wang W; Li K; Sun Q; Ren Y; Su W
    Clin Cancer Res; 2019 Jun; 25(12):3486-3494. PubMed ID: 30833272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surufatinib for the treatment of advanced extrapancreatic neuroendocrine tumors.
    Lu X; Yan S; Koral KA; Chen Z
    Expert Rev Anticancer Ther; 2021 Sep; 21(9):917-926. PubMed ID: 34142932
    [No Abstract]   [Full Text] [Related]  

  • 9. A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors.
    Dasari A; Hamilton EP; Falchook GS; Wang JS; Li D; Sung MW; Chien C; Nanda S; Tucci C; Hahka-Kemppinen M; Paulson AS
    Invest New Drugs; 2023 Jun; 41(3):421-430. PubMed ID: 37074571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trial.
    Zhang P; Shi S; Xu J; Chen Z; Song L; Zhang X; Cheng Y; Zhang Y; Ye F; Li Z; Yin F; Ji D; Gao H; Li Y; Chen W; Yang M; Weng D; Wu C; Ma Y; Sheng W; Zhao Y; Yin X; Shen W; Su W; Shi M; Fan S; Tan P; Xu Q; Lu M; Shen L
    Eur J Cancer; 2024 Mar; 199():113539. PubMed ID: 38237373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the effectiveness and safety of surufatinib versus everolimus or sunitinib in advanced neuroendocrine neoplasms: insights from a real-world, retrospective cohort study using propensity score and inverse probability treatment weighting analysis.
    Zhu L; Ye X; She Y; Liu W; Hasegawa K; Rossi RE; Du Q; Zhai Q
    J Gastrointest Oncol; 2024 Apr; 15(2):689-709. PubMed ID: 38756630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of surufatinib in the treatment of advanced solid tumors: a systematic evaluation and meta‑analysis.
    Cai T; Cheng Y; Du Y; Tan P; Li T; Chen Y; Gao L; Fu W
    Oncol Lett; 2023 Jun; 25(6):273. PubMed ID: 37216159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surufatinib in Chinese Patients with Locally Advanced or Metastatic Differentiated Thyroid Cancer and Medullary Thyroid Cancer: A Multicenter, Open-Label, Phase II Trial.
    Chen J; Ji Q; Bai C; Zheng X; Zhang Y; Shi F; Li X; Tang P; Xu Z; Huang R; Huang T; Pan Y; Fan S; Zhou J; Su W
    Thyroid; 2020 Sep; 30(9):1245-1253. PubMed ID: 32075524
    [No Abstract]   [Full Text] [Related]  

  • 14. Surufatinib: First Approval.
    Syed YY
    Drugs; 2021 Apr; 81(6):727-732. PubMed ID: 33788183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current treatments and future potential of surufatinib in neuroendocrine tumors (NETs).
    Xu J
    Ther Adv Med Oncol; 2021; 13():17588359211042689. PubMed ID: 34484432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chinese multidisciplinary expert consensus on the rational use of surufatinib in clinical practice（2024 edition）].
    Chinese Multidisciplinary Expert Consensus on the Rational Use of Surufatinib in Clinical Practice-Editorial Board Group
    Zhonghua Zhong Liu Za Zhi; 2024 Oct; 46(10):930-939. PubMed ID: 39414593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline radiologic features as predictors of efficacy in patients with pancreatic neuroendocrine tumors with liver metastases receiving surufatinib.
    Zhang J; Zhu H; Shen L; Li J; Zhang X; Bai C; Zhou Z; Yu X; Li Z; Li E; Yuan X; Lou W; Chi Y; Xu N; Yin Y; Bai Y; Zhang T; Xiu D; Chen J; Qin S; Wang X; Yang Y; Shi H; Luo X; Fan S; Su W; Lu M; Xu J
    Chin J Cancer Res; 2023 Oct; 35(5):526-535. PubMed ID: 37969958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A single-arm, multicenter, open-label phase 2 trial of surufatinib in patients with unresectable or metastatic biliary tract cancer.
    Xu J; Bai Y; Sun H; Bai C; Jia R; Li Y; Zhang W; Liu L; Huang C; Guan M; Zhou J; Su W
    Cancer; 2021 Nov; 127(21):3975-3984. PubMed ID: 34355801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
    Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M
    Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
    Raymond E; Dahan L; Raoul JL; Bang YJ; Borbath I; Lombard-Bohas C; Valle J; Metrakos P; Smith D; Vinik A; Chen JS; Hörsch D; Hammel P; Wiedenmann B; Van Cutsem E; Patyna S; Lu DR; Blanckmeister C; Chao R; Ruszniewski P
    N Engl J Med; 2011 Feb; 364(6):501-13. PubMed ID: 21306237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.